You are in: eMedicine Specialties > Infectious Diseases > MEDICAL TOPICS Pasteurella Multocida InfectionArticle Last Updated: Apr 5, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Thomas Lafeber, MD, Consulting Staff, Wellstar Infectious Disease LLC Thomas Lafeber is a member of the following medical societies: American Medical Association, American Society of Transplantation, and Infectious Diseases Society of America Coauthor(s): J Robert Cantey, MD, Chief of Infectious Disease, Veterans Affairs Medical Center, Director, Professor, Department of Medicine, Division of Infectious Diseases, Medical University of South Carolina Editors: Larry I Lutwick, MD, Professor of Medicine, State University of New York, Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Aaron Glatt, MD, Professor of Clinical Medicine, New York Medical College; Chief Medical Officer, Departments of Medicine and Infectious Diseases, New Island Hospital; Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital; Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital Author and Editor Disclosure Synonyms and related keywords: P multocida, coccobacillus, coccobacilli, bacterial infection, dog bite, cat bite, cat scratch, bite wound, animal bite wound, cat lick, pet wound, pet bite, meningitis, tetanus, rabies INTRODUCTIONBackgroundPasteurella multocida is a small, gram-negative, non–spore-forming coccobacillus with bipolar staining, often existing as a commensal in the upper respiratory tract of many livestock, poultry, and domestic pet species. Infection in humans is often associated with an animal bite, scratch, or lick, but infection without epidemiologic evidence of animal contact may occur. Local wound infections from animal bites are the most common human infections caused by P multocida, although a vast array of infectious syndromes may be observed (see Pathophysiology). Co-infection with multiple aerobic and anaerobic organisms is common in animal bite wound infections, and P multocida is one of the most common organisms found in culture. Physicians must determine the risk of polymicrobial infection, which sometimes mandates the use of broad-spectrum antibiotics. Rare cases of P multocida meningitis in young children may mimic Haemophilus influenzae or Neisseria meningitidis on cerebrospinal fluid Gram stain results. A history of pet exposure should alert the physician to this possibility. Pathophysiology
FrequencyUnited StatesMore than 100 million dogs and cats live in the United States. According to estimates, half of all Americans will be bitten in their lifetime—most by provoked dogs. Other injuries, such as cat scratches, are documented less often in emergency department statistics. Approximately 5% of dog bites and 30% of cat bites become infected. InternationalP multocida infections occur worldwide. Mortality/MorbiditySee Pathophysiology. AgeCNS diseases caused by P multocida infection typically occur in persons at the extremes of age. CLINICALHistory
PhysicalPhysical findings relate to the site of infection, as follows:
DIFFERENTIALSAbdominal Abscess Amebic Hepatic Abscesses Brain Abscess Catscratch Disease Cellulitis HACEK Group Infections Haemophilus Influenzae Infections Intra-abdominal Sepsis Liver Abscess Lung Abscess Meningitis Meningococcal Infections Perinephric Abscess Pneumonia, Bacterial Pneumonia, Community-Acquired Pyelonephritis, Acute
|
| Drug Name | Amoxicillin and clavulanate (Augmentin) |
|---|---|
| Description | Drug combination treats bacteria resistant to beta-lactam antibiotics. For children > 3 mo, base dosing protocol on amoxicillin content. Because of different ratios of amoxicillin to clavulanic acid in 250-mg tab (250:125) vs 250-mg chewable tab (250:62.5), do not use 250-mg tab until child weighs >40 kg. |
| Adult Dose | 500-875 mg PO q12h or 250-500 mg PO q8h |
| Pediatric Dose | <40 kg: 20-40 mg/kg/d PO divided bid >40 kg: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with warfarin or heparin increases risk of bleeding |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal impairment; may increase risk of candidiasis |
| Drug Name | Cefuroxime (Ceftin, Zinacef) |
|---|---|
| Description | Second-generation cephalosporin that maintains gram-positive activity of first-generation cephalosporins; adds activity against Proteus mirabilis, H influenzae, Escherichia coli, Klebsiella pneumoniae, and Moraxella catarrhalis. Condition of patient, severity of infection, and susceptibility of microorganism determine proper dose and route of administration. |
| Adult Dose | 500 mg PO bid; alternatively, 750-1500 mg IV/IM q8h; not to exceed 6 g/d |
| Pediatric Dose | Children: 250 mg PO bid Adolescents: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Disulfiramlike reactions may occur when alcohol is consumed within 72 h after administration; may increase hypoprothrombinemic effects of anticoagulants; may increase nephrotoxicity in patients receiving potent diuretics (eg, loop diuretics); coadministration with aminoglycosides increase nephrotoxic potential |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Reduce dosage by half if CrCl is 10-30 mL/min and by three quarters if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy |
| Drug Name | Doxycycline (Vibra-Tabs, Bio-Tab, Doryx, Vibramycin) |
|---|---|
| Description | Inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. |
| Adult Dose | 200 mg PO/IV immediately, followed by 100-200 mg PO q12h |
| Pediatric Dose | <8 years: Not recommended >8 years: 2-5 mg/kg/d PO/IV qd or divided bid; not to exceed 200 mg/d |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy |
| Pregnancy | D - Unsafe in pregnancy |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last half of pregnancy through 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Penicillin G (Pfizerpen) |
|---|---|
| Description | Inhibits biosynthesis of cell wall mucopeptide. Bactericidal against sensitive organisms when adequate concentrations are reached. Most effective during the stage of active multiplication. Inadequate concentrations may produce only bacteriostatic effects. Use penicillin VK for PO or penicillin G for IV. |
| Adult Dose | 2.4 million U IM (single dose) in 2 injection sites |
| Pediatric Dose | 50,000 U/kg IM; not to exceed 2.4 million U |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effectiveness by decreasing clearance; tetracyclines are bacteriostatic, causing a decrease in the effectiveness of penicillins when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in renal impairment |
| Drug Name | Ampicillin and sulbactam (Unasyn) |
|---|---|
| Description | Drug combination of beta-lactamase inhibitor with ampicillin. Covers skin, enteric flora, and anaerobes. Not ideal for nosocomial pathogens. |
| Adult Dose | 1.5 (1 g ampicillin + 0.5 g sulbactam) to 3 g (2 g ampicillin + 1 g sulbactam) IV/IM q6h; not to exceed 4 g/d sulbactam or 8 g/d ampicillin |
| Pediatric Dose | 3 months to 12 years: 100-200 mg ampicillin/kg/d (150-300 mg Unasyn) IV divided q6h >12 years: Administer as in adults; not to exceed 4 g/d sulbactam or 8 g/d ampicillin |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of oral contraceptives |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction |
| Drug Name | Ticarcillin and clavulanate (Timentin) |
|---|---|
| Description | Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active growth. Antipseudomonal penicillin plus beta-lactamase inhibitor that provides coverage against most gram-positive organisms, most gram-negative organisms, and most anaerobes. |
| Adult Dose | 3.1 g (3 g ticarcillin and 0.1 g clavulanate) IV q6h |
| Pediatric Dose | 75 mg/kg IV q6h |
| Contraindications | Documented hypersensitivity; severe pneumonia, bacteremia, pericarditis, emphysema, meningitis, and purulent or septic arthritis should not be treated with oral penicillin during acute stage |
| Interactions | Tetracyclines may decrease effects of ticarcillin; high concentrations of ticarcillin may physically inactivate aminoglycosides if administered in same IV line; effects are synergistic when administered concurrently with aminoglycosides; probenecid may increase penicillin levels |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Perform CBC count prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; exercise caution in patients with hepatic insufficiencies; perform urinalysis and BUN and creatinine determinations during therapy and adjust dose if values become elevated; monitor blood levels to avoid possible neurotoxic reactions |
| Drug Name | Ciprofloxacin (Cipro) |
|---|---|
| Description | Mode of action of all quinolones involves inhibition of bacterial DNA synthesis by blocking the enzyme DNA gyrase |
| Adult Dose | 250-500 mg PO bid |
| Pediatric Dose | <18 years: Not recommended >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Antacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; reduces therapeutic effects of phenytoin; probenecid may increase serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy |
| Drug Name | Amoxicillin (Trimox, Amoxil) |
|---|---|
| Description | Interferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria. |
| Adult Dose | 1 g PO q8h; not to exceed 3 g/d |
| Pediatric Dose | 20-50 mg/kg/d PO divided q8h; not to exceed 2 g/dose |
| Contraindications | Documented hypersensitivity |
| Interactions | Reduces efficacy of oral contraceptives |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal impairment; may increase risk of candidiasis |
| Drug Name | Levofloxacin (Levaquin) |
|---|---|
| Description | For pseudomonal infections and infections due to multidrug-resistant gram-negative organisms. |
| Adult Dose | 500 mg PO qd |
| Pediatric Dose | <18 years: Not recommended >18 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Antacids, iron salts, and zinc salts may reduce serum levels; administer antacids 2-4 h before or after taking fluoroquinolones; cimetidine may interfere with metabolism of fluoroquinolones; reduces therapeutic effects of phenytoin; probenecid may increase serum concentrations; may increase toxicity of theophylline, caffeine, cyclosporine, and digoxin (monitor digoxin levels); may increase effects of anticoagulants (monitor PT) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy |
| Drug Name | Ampicillin (Principen, Omnipen) |
|---|---|
| Description | Bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take medication PO. |
| Adult Dose | 250-500 mg PO q6h 2 g IV/IM q4h Not to exceed 12 g/d |
| Pediatric Dose | 50-100 mg/kg/d PO divided q4-6h 100-400 mg/kg/d IV/IM divided q4-6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate levels; allopurinol decreases effects and has additive effects on ampicillin rash; may decrease effects of oral contraceptives |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction |
Pasteurella Multocida Infection excerpt
Article Last Updated: Apr 5, 2006